### Overview

Lemtrada is a monoclonal antibody disease-modifying drugs indicated for relapsing remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (SPMS) in adults.

**FDA Approved indication:** Lemtrada is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

All other indications are considered experimental/investigational and are not covered benefits.

### Coverage Guidelines

**First Course – Relapsing forms of multiple sclerosis**

Authorization of 30 days (5 doses) may be granted to members with a diagnosis of a relapsing form of multiple sclerosis who have had an inadequate response to two or more drugs indicated for multiple sclerosis.

**Second Course – Relapsing forms of multiple sclerosis**

Authorization of 30 days (3 doses) may be granted to members with a diagnosis of a relapsing form of multiple sclerosis who have completed one previous course of therapy.

### Limitations

All approvals will be granted for 30 days.

### References

**Review History**
11/18/2020 – Transitioned from SGM to Custom Criteria; separated MH vs. Comm/Exch

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.